AstraZeneca has terminated all development of vemircopan, the oral factor D inhibitor it acquired through the deal for ...
It took one month for Johnson & Johnson to secure its $14 billion acquisition of Intra-Cellular Therapies, according to new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback